Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways

Madhumitha Kedhari Sundaram1, Shafiul Haque2, Pallavi Somvanshi3

  • 1School of Life Sciences, Manipal Academy of Higher Education, PO Box 345050, Dubai, United Arab Emirates.

3 Biotech
|October 29, 2020
PubMed

Insights

Epigallocatechin gallate (EGCG) reverses cervical cancer cell growth by modulating epigenetic enzymes, reactivating tumor suppressor genes, and altering cancer-related signaling pathways. This natural compound shows significant anti-cancer potential through synchronized molecular targeting.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Cancer Research

Background:

  • Cervical cancer remains a significant global health challenge.
  • Epigenetic dysregulation plays a crucial role in cancer development and progression.
  • Natural compounds like epigallocatechin gallate (EGCG) are being investigated for their therapeutic potential.

Purpose of the Study:

  • To investigate the anti-cancer effects of EGCG on cervical cancer cells (HeLa).
  • To elucidate EGCG's impact on epigenetic modulators, signaling pathways, and tumor suppressor genes.
  • To understand the molecular mechanisms underlying EGCG's anti-cancer activity.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to assess gene transcription.
  • ELISA-based enzymatic assays to measure enzyme activity.
  • In silico molecular docking and protein-protein interaction network analysis.
  • Quantitative methylation array analysis.

Main Results:

  • EGCG modulated the transcription of various epigenetic modifiers, including DNA methyltransferases and histone modifiers.
  • EGCG reduced the activity of DNA methyltransferases, histone deacetylases, and histone methyltransferases.
  • EGCG treatment led to the re-expression of silenced tumor suppressor genes (e.g., TP73, PTEN, SOCS1) by reversing promoter hypermethylation.
  • EGCG downregulated key signaling pathways (PI3K, Wnt, MAPK), cell cycle regulators, metastasis, and pro-inflammatory factors.
  • In silico analyses confirmed EGCG's potential to inhibit epigenetic enzymes and identified its role in cancer pathways.

Conclusions:

  • EGCG exhibits anti-cancer properties in cervical cancer cells by targeting multiple molecular mechanisms.
  • EGCG modulates epigenetic enzymes, leading to the reactivation of tumor suppressor genes.
  • EGCG's synchronized alteration of signaling pathways and epigenetic landscape contributes to its anti-cancer effects.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K